新诊断转移性三阴性乳腺癌老年患者接受的治疗方案数量对总生存期、成本和医疗资源使用的影响。
Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer.
机构信息
Pharmerit International, 4350 East-West Hwy, Suite 1110, Bethesda, MD 20814, USA.
Celldex Therapeutics, 53 I-78 Frontage Rd, Hampton, NJ 08827, USA.
出版信息
Future Oncol. 2019 Mar;15(9):1007-1020. doi: 10.2217/fon-2018-0407. Epub 2019 Feb 5.
AIM
This analysis estimated the overall survival, treatment patterns and economic burden of elderly metastatic triple-negative breast cancer patients.
MATERIALS & METHODS: Patients (≥66 years) with metastatic triple-negative breast cancer were identified from the SEER-Medicare database. Treatment patterns were defined in terms of first, second and third or more regimens. Healthcare resource use and costs were reported over the follow-up period and over the treatment duration of each regimen.
RESULTS
A total of 51% of patients did not receive chemotherapy. Taxanes were most commonly used. Median survival was 7 months. The mean cumulative (per patient per month) cost per patient was US$73,586 (US$10,084). Mean cost in first and second regimen were US$26,950 and US$33,347.
CONCLUSION
About half of patients did not receive chemotherapy. Receipt of increasing regimens led to higher mean costs and healthcare resource use.
目的
本分析评估了老年转移性三阴性乳腺癌患者的总生存期、治疗模式和经济负担。
材料与方法
从 SEER-Medicare 数据库中确定了患有转移性三阴性乳腺癌的患者（≥66 岁）。根据一线、二线和三线或更多线治疗方案来定义治疗模式。报告了随访期间和每个治疗方案期间的医疗资源使用和成本。
结果
共有 51%的患者未接受化疗。紫杉烷类药物最常用。中位生存期为 7 个月。每位患者每月的累积（每位患者每月）成本为 73586 美元（10084 美元）。一线和二线方案的平均费用分别为 26950 美元和 33347 美元。
结论
约一半的患者未接受化疗。接受更多的治疗方案会导致更高的平均成本和医疗资源使用。
Zotero 插件